XML 76 R67.htm IDEA: XBRL DOCUMENT v3.25.3
Collaborations, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 31, 2018
Aug. 31, 2025
Dec. 31, 2023
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
May 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Deferred revenue - current       $ 10,123,000   $ 10,123,000   $ 12,407,000  
Deferred revenue - non-current       48,194,000   48,194,000   51,160,000  
Total revenue from UT       82,130,000 $ 70,079,000 237,011,000 $ 208,728,000    
Amphastar                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Performance obligation transaction price           2,500,000      
Performance obligation transaction price recognized       500,000   1,500,000      
Performance obligation transaction price yet to recognize           500,000      
Manufacturing Services                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total revenue from UT       0 300,000 1,200,000 1,700,000    
Collaborations and services                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total revenue from UT       26,506,000 23,268,000 78,727,000 74,130,000    
AFREZZA product sales                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total revenue from UT       22,305,000 19,728,000 63,732,000 59,272,000    
United Therapeutics Corporation                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total revenue from UT       59,288,000 50,314,000 171,563,000 149,346,000    
United Therapeutics Corporation | Facility Expansion Services                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Deferred revenue       52,200,000   52,200,000      
Collaboration and License Agreement | United Therapeutics Corporation                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Deferred revenue       57,200,000   57,200,000   62,400,000  
Deferred revenue - current       10,000,000   10,000,000   12,300,000  
Deferred revenue - non-current       47,200,000   $ 47,200,000   100,000  
Royalty percentage 10.00%         10.00%      
Royalty future net sales percentage     1.00%            
Royalty retaining percentage     9.00%            
License agreement description           There have been various amendments to the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA      
Collaboration and License Agreement | United Therapeutics Corporation | Other Administrative Services                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Deferred revenue       61,300,000   $ 61,300,000      
Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total revenue from UT       25,969,000 23,231,000 77,011,000 73,673,000    
Co-Promotion Agreement | Collaborations and services | Amphastar                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total revenue from UT       500,000   1,500,000      
Supply and Distribution Agreement | AFREZZA product sales | Biomm                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total revenue from UT           0      
License and Distribution Agreement | Cipla Ltd                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Deferred revenue       1,100,000   1,100,000   1,200,000  
Deferred revenue - current       100,000   100,000   100,000  
Deferred revenue - non-current       1,000,000   $ 1,000,000   1,100,000  
Marketing and distribution agreement date           2018-05      
Milestone payments               $ 1,100,000  
License and Distribution Agreement | Collaborations and services | Cipla Ltd                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total revenue from UT       $ 37,000 $ 37,000 $ 110,000 $ 110,000    
License and Distribution Agreement | Nonrefundable Licensing Fee                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Deferred revenue                 $ 2,200,000
UT License Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Upfront payment received   $ 5,000,000              
Development milestones   $ 35,000,000              
Percentage of royalty on net sales   10.00%              
UT License Agreement | Current Stage of Development and Achievement Criteria                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Development milestones   $ 10,000,000              
UT License Agreement | Constrained                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Development milestones   $ 30,000,000